Antibodies to CD40 with enhanced agonist activity

US10479838B2 · kind B2 · utility

Assignees

• Bristol-Myers Squibb Company · US
• The Rockefeller University · US

Inventors

• Jeffrey V. Ravetch · New York, US
• Rony Dahan · Mazkeret Batya, IL
• Bryan C. BARNHART · San Francisco, US
• Brigitte Devaux · Palo Alto, US
• Aaron P. YAMNIUK · Lawrenceville, US
• Shannon L. Okada · Seattle, US
• Brenda L. Stevens · Seattle, US

Key dates

• Filing date: Jun 28, 2016
• Grant date: Nov 19, 2019
• Expiry date: Aug 5, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.